Why the Pharmaxis (ASX:PXS) share price jumped 6% today

The Pharmaxis Ltd (ASX: PXS) share price is up 6% during early afternoon trade. We look at the announcement driving the share price moves.

| More on:
medical asx share price represented by doctor giving thumbs up

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The Pharmaxis Ltd (ASX: PXS) share price is up today on the news it has received a substantial payment from a strategic partner.

The Pharmaxis share price reached an intraday high of 9.9 cents in late morning trade, but has since pulled back. At the time of writing, the Pharmaxis shares are up 6.8% to 9.3 cents.

What does Pharmaxis do?

Pharmaxis is an Australian biotechnology company committed to research and drug development for diseases involving inflammation and fibrosis including cystic fibrosis, pulmonary fibrosis and liver disease.

The company currently has two respiratory products approved in international markets that are generating recurring revenue. In addition, Pharmaxis has a diversified range of products at various stages of development.

Milestone payment

Pharmaxis advised this morning that it's received a milestone payment of US$7 million ($9.2 million) from its United States licensee, Chiesi.

According to the company, the credited funds follow the recent approval by the United States Food and Drug Administration (FDA) for Bronchitol.

Bronchitol is used for the treatment of cystic fibrosis in helping a patient clear mucus from their lungs. A spray-dried form of the active ingredient, mannitol, is delivered to the lungs by a specially designed, portable inhaler. Bronchitol works by rehydrating the airway/lung surface and promoting a productive cough.

The product is also sold and marketed across Europe, Russia, and Australia.

With the first payment received, Pharmaxis is anticipating a further US$3 million from Chiesi on the shipment of Bronchitol. The United States bound delivery is scheduled for the first quarter of 2021.

Reporting a cash holding of $10 million at the end of the last September period, the company has since bulked up its coffers. Pharmaxis recently added a $5 million R&D tax incentive in October, bringing its total cash balance to $24.2 million, including the $9.2 million payment.

How has the Pharmaxis share price performed in 2020?

The Pharmaxis share price is down almost 40% over the past 12 months. Its shares reached an all-time low of 5.3 cents in March and have failed to recover from its highs recorded at the start of the year.

The height of the Pharmaxis share price reached was 11 cents in April, straight after the pandemic took the world hostage. Since then, Pharmaxis shareholders have been going on a mini-rollercoaster ride.

Aaron Teboneras has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. owns shares of Pharmaxis Ltd. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

More on Share Market News

a man weraing a suit sits nervously at his laptop computer biting into his clenched hand with nerves, and perhaps fear.
Share Fallers

Why Evolution Mining, G8 Education, Lottery Corp, and Lynas shares are tumbling today

These shares are ending the week in the red. But why?

Read more »

A businessman lights up the fifth star in a lineup, indicating positive share price for a top performer
Broker Notes

Bell Potter names more of the best ASX 200 stocks to buy in July

These stocks could be best buys this month according to the broker.

Read more »

A man has a surprised and relieved expression on his face. as he raises his hands up to his face in response to the high fluctuations in the Galileo share price today
Broker Notes

Macquarie tips 55% upside for this ASX mining stock

Let's see what the broker is saying about this stock.

Read more »

Five people in an office high five each other.
Technology Shares

5 best performing ASX 200 tech shares of FY25

Some of the technology sector's biggest names led the charge in share price growth last financial year.

Read more »

A concerned man looking at his laptop.
Broker Notes

Why this broker just downgraded Pro Medicus shares

Let's see what Bell Potter is saying about this high-flying stock.

Read more »

Share Market News

5 things to watch on the ASX 200 on Friday

A good finish to the week is expected for Aussie investors.

Read more »

A young male ASX investor raises his clenched fists in excitement because of rising ASX share prices today
Share Gainers

3 ASX shares that rose 100%+ in FY25

Let's see why these shares delivered huge returns for their shareholders in the last financial year.

Read more »

Man pointing at a blue rising share price graph.
Resources Shares

Up 275% in a year, why this ASX All Ords mining stock could keep racing higher into 2026

A leading fund manager forecasts more outperformance to come for this rocketing ASX All Ords miner. But why?

Read more »